NICE To Hear Appeals On Alzheimer’s Appraisal
This article was originally published in The Pink Sheet Daily
The U.K. National Institute for Health & Clinical Excellence will hear five appeals against a final appraisal determination that limits recommended National Health Service coverage of four Alzheimer's disease treatments
You may also be interested in...
National Institute for Health & Clinical Excellence recommends limited use of acetylcholinesterase inhibitors, finds against Namenda.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.